1 1

Tesamorelin

Tesamorelin

Dual-Chamber Pen

Tesamorelin Peptide Pen is available in a 20 mg strength and contains a synthetic analogue of growth hormone-releasing hormone (GHRH). Tesamorelin has been extensively studied for its ability to stimulate the body’s own growth hormone and IGF-1 pathways, with clinical research reporting notable effects on visceral abdominal fat and body composition.

Unlike Somatropin, which directly provides growth hormone, Tesamorelin acts through the GHRH receptor, stimulating growth-hormone release through the body’s existing endocrine pathway. This makes it particularly interesting for research into fat metabolism, body composition and GH–IGF-1 signalling.

PCP’s proprietary Dual-Chamber Technology keeps the lyophilised Tesamorelin separate from the bacteriostatic water until activation.

For laboratory research use only. Not intended for human or veterinary use.

Strength
€105,95 EUR
€105,95 EUR
Sale Sold out
Taxes included. Shipping calculated at checkout.
Fast, Tracked Shipping
Secure Checkout
COA Available With Lot
Expert Support
Product Details

The Tesamorelin Dual-Chamber Peptide Pen is supplied in a preloaded format that keeps the lyophilised Tesamorelin powder and diluent in separate chambers until preparation. This allows both components to remain unmixed throughout storage and transport.

Each pen is clearly identified and professionally packaged, providing qualified researchers with a protected, convenient format for controlled preparation and consistent laboratory handling.

Product highlights:

• Dual-chamber configuration with separately contained Tesamorelin powder and diluent
• Components remain unmixed until laboratory preparation
• Available in a 20 mg strength
• Provides 100 dial units in total
• One complete dual-chamber cartridge per pen
• Five 32G × 4 mm needle tips included
• Protective packaging for storage and transport
• Certificate of Analysis (COA) available

Technical specifications, dial-unit information, storage requirements and handling guidance are provided to support confident product identification and responsible laboratory use.

Technical Specifications
Intended Use
For laboratory research use only. Not for human or veterinary use.
Shipping Condition
Securely packaged for transport with tracked delivery.
Storage Temperature
Unopened/unmixed: store refrigerated at 2–8°C. After mixing: store refrigerated at 2–8°C. Do not freeze. Protect from light.
Presentation
One pre-filled double-chamber research pen containing unmixed components, supplied with three 32G × 4 mm needle tips
Form
Lyophilized peptide powder and diluent maintained in separate chambers
Compound Identity
Compound: Tesamorelin

Compound type: Synthetic N-terminally modified 44-amino-acid analogue of human growth hormone-releasing hormone (GHRH)

Research classification: GHRH-receptor agonist investigated in connection with neuroendocrine signalling, growth-hormone regulation, IGF-1-associated pathways and metabolic processes

Refer to the applicable product and batch documentation for verified analytical and chemical identity information.
Pen Specifications

Each pen contains a 1 mL cartridge. The amount represented by one dial unit depends on the selected pen strength. The tables below show the corresponding values for each available strength.

Pen Specifications
Pen strength Cartridge 1 dial unit
20 mg 1 mL 0.2 mg

Dial-Unit Conversion Reference

The table shows the amount represented by each listed dial setting for the available pen strengths.

Dial-unit reference by pen strength
Dial units 20 mg
1 0.2 mg
4 0.8 mg
5 1.0 mg
10 2.0 mg
20 4.0 mg
40 8.0 mg

Research-use information: Dial-unit values are provided solely for product identification, quantitative laboratory planning and documentation. They are not administration or clinical dosing instructions.

Storage & Handling

Recommended storage: Unopened/unmixed: store refrigerated at 2–8°C. After mixing: store refrigerated at 2–8°C. Do not freeze. Protect from light.

Protect the product from light and moisture and minimise unnecessary exposure to room temperature.

Complete storage and handling guidance is provided in the product information section below.

Research Use Only

All Pencell Peptide (PCP) products are supplied exclusively for laboratory research use by qualified professionals. They are not intended for human or veterinary use, consumption, personal use, medical, therapeutic, or diagnostic applications. Customers are responsible for lawful purchase, storage, handling, use, and disposal in accordance with applicable regulations and approved laboratory procedures.

View full details

Protected by Design

Peptide and diluent remain separate until preparation

≥98% Purity

HPLC verified for research grade quality

Controlled Conditions

Prepared with a focus on consistency and research quality

Certificate of Analysis

Provided with Every Lot

Scientific Overview

Scientific Background

Tesamorelin is a synthetic peptide composed of 44 amino acids and closely modelled on the complete sequence of naturally occurring human growth hormone-releasing hormone (GHRH). Rather than substantially changing this sequence, Tesamorelin adds a targeted trans-3-hexenoic acid modification at the N-terminus, increasing resistance to enzymatic breakdown while preserving activity at the GHRH receptor.

Activation of the GHRH receptor stimulates the body’s growth-hormone signalling pathway, leading to increased growth-hormone release and downstream production of insulin-like growth factor 1 (IGF-1). This distinguishes Tesamorelin from compounds that provide growth hormone directly and makes it particularly useful for studying the body’s own GH–IGF-1 regulatory pathway.

Its molecular design also provides an important example of how a relatively small structural modification can improve peptide stability and duration of activity without replacing the underlying biological sequence. Researchers can compare Tesamorelin with natural GHRH to investigate differences in receptor binding, signalling, enzymatic stability and downstream gene expression.

These characteristics connect Tesamorelin’s molecular structure with the wider biological processes observed in research, including growth-hormone regulation, fat metabolism, body composition and endocrine signalling.

This information is provided as general scientific background for laboratory research purposes.
Research Context

Research Applications

Areas examined within controlled laboratory research.

Tesamorelin is a synthetic 44-amino-acid analogue of human growth hormone-releasing hormone (GHRH). Its sequence closely follows naturally occurring GHRH but includes a trans-3-hexenoic acid modification at the N-terminus, which improves resistance to enzymatic breakdown while preserving activity at the GHRH receptor.

By activating this receptor, Tesamorelin stimulates the growth hormone–IGF-1 pathway rather than acting as growth hormone itself. This distinction makes it particularly interesting for studying how the body’s own growth-hormone signalling influences fat metabolism, body composition and broader endocrine regulation.

Clinical and experimental research has examined Tesamorelin particularly in relation to visceral abdominal fat, alongside changes in growth hormone secretion, IGF-1 signalling and metabolic pathways. Its modified structure also provides a useful model for understanding how small changes to a peptide can improve stability while maintaining receptor activity.

Current areas of scientific investigation include:

  1. GHRH-receptor signalling (Tesamorelin)

    Research examining how Tesamorelin interacts with the growth hormone-releasing hormone receptor and influences downstream intracellular signalling pathways.

  2. Growth-hormone regulation (Tesamorelin)

    Studies exploring Tesamorelin in experimental models associated with the synthesis, release and regulation of growth hormone.

  3. IGF-1-associated pathways (Tesamorelin)

    Investigation of downstream signalling responses involving insulin-like growth factor 1 and its relationship with the wider growth hormone axis.

  4. Peptide stability and enzymatic resistance (Tesamorelin)

    Research evaluating how Tesamorelin’s N-terminal modification influences molecular stability and resistance to enzymatic degradation.

  5. Neuroendocrine communication (Tesamorelin)

    Studies examining the signalling relationships connecting GHRH-receptor activity, pituitary responses and wider endocrine regulation.

  6. Metabolic and gene-expression responses (Tesamorelin)

    Experimental investigation of metabolic signalling and gene-expression patterns associated with Tesamorelin under controlled research conditions.

Studies of Tesamorelin have provided important insight into the relationship between GHRH signalling, growth hormone release and body-fat distribution. Clinical research has reported significant reductions in visceral abdominal fat, alongside increases in IGF-1, making Tesamorelin particularly relevant to research into the GH–IGF-1 pathway and metabolic regulation.

Unlike direct growth-hormone administration, Tesamorelin works by activating the GHRH receptor, allowing researchers to investigate stimulation of the body’s own growth-hormone pathway and the downstream biological responses that follow.

Research continues to examine how these effects relate to fat metabolism, body composition, endocrine signalling and glucose and lipid metabolism, as well as how Tesamorelin’s modified structure contributes to its stability and biological activity.

For laboratory research purposes only. Not intended for human or veterinary use.

Important Notice Research Use Only View complete notice

All products supplied by Pencell Peptide (PCP), including its dual-chamber peptide research pens, are intended strictly for laboratory research purposes only.

These products are not intended for human or animal consumption, medical or veterinary use, therapeutic applications, diagnostic procedures or any other clinical purpose.

Customers are responsible for complying with all applicable laws, regulations and institutional requirements governing the purchase, possession, handling, storage and use of peptide research materials.

Read the complete Research Use Only notice .